On February 12, 2024, Skye Bioscience, Inc., closed the transaction. The company has raised $49,991,010 from 11 investors. The company paid sales commission of $3,499,371 in the transaction.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.02 USD | +1.78% |
|
-11.31% | +191.18% |
06-24 | Skye Bioscience, Inc.(NasdaqGM:SKYE) added to S&P TMI Index | CI |
06-10 | Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+191.18% | 221M | |
+26.48% | 52.73B | |
+37.49% | 39B | |
-9.23% | 38.52B | |
+28.95% | 30.38B | |
-12.26% | 26.39B | |
+10.67% | 26.08B | |
+45.20% | 14.15B | |
+32.44% | 12.6B | |
-6.06% | 11.51B |
- Stock Market
- Equities
- EMBI Stock
- News Skye Bioscience, Inc.
- Skye Bioscience, Inc. announced that it has received $49.99101 million in funding